Zinzino AB (publ)
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Zinzino AB (publ) (ZNZNF) is a Sweden-based direct sales company specializing in test-based, personalized nutrition, dietary supplements, skincare, and lifestyle products. Founded in 2005 and headquartered in Vstra Frlunda near Gothenburg, the company operates through two main segments, Zinzino and Faun, marketing its offerings via a global network of distributors and online platforms targeting health-conscious consumers in over 100 markets across Europe, North America, Asia-Pacific, and emerging regions. Zinzino provides a comprehensive range of core products including home health tests such as BalanceTest for omega levels and the newly launched Gut Health Test utilizing metabolomics for blood-based analysis of gut bacteria signals; nutritional supplements encompassing immune support, omega-3 formulations like BalanceOil, restored blends, and cellular-level nutrition protocols; weight management solutions; gut health supplements; skincare items comprising cleansers, face creams, serums, masks, and collagen gels; as well as beverages through Zinzino Coffee featuring espresso machines, coffee, tea, accessories, and cups. The company owns research subsidiary BioActive Foods AS and production unit Faun Pharma AS, supporting its science-backed, subscription-based model that pairs tests with tailored monthly refills and personal wellness consultants. In recent developments, Zinzino has aggressively expanded its distribution power through multiple strategic asset acquisitions in 2025, including Zurvita, Valentus, Ecosystem for French and Dom-Tom markets with SEK 40 million turnover, Bode Pro, and Truvy generating USD 12 million annually to bolster North America and Latin America presence; earlier moves encompassed VMA Life in 2020, Enhanzz in 2022, and Xelliss with ACN in 2024. Additionally, Zinzino launched operations in New Zealand on March 11, 2025, as part of its global push toward 1 million customers by year-end, while posting accumulated January-November 2025 revenues of SEK 3,007.5 million, up 54% year-over-year, alongside innovations like pioneering finger-prick gut health testing introduced in October 2025. These initiatives underscore Zinzino's focus on sustainable profitable growth, technological infrastructure, and synergies from integrated distributor networks and product portfolios.
ZINZINO AB (PUBL.): YEAR-END REPORT 2025
ZINZINO AB (PUBL.): ZINZINO ANNOUNCES PERU AS NEXT STEP IN ITS GLOBAL EXPANSION
ZINZINO AB (PUBL): Zinzino announces merger of It Works! into the Zinzino family of businesses for increased distribution power in North America and Europe
Zinzino AB (publ.): Interim Report for the third quarter of 2025
Zinzino AB (publ.): Zinzino acquires 35% of the shares in Andorra-based Xion International Group for further development of its own-produced omega-3 oil and spirulina
Zinzino AB (publ.): Zinzino acquires Mexican company Sanki to increase distribution capacity in North America and South America
Zinzino AB (publ.): Pioneering Gut Health Testing With a Simple Finger Prick
ZINZINO AB (PUBL.): ZINZINO ACQUIRES TRUVY TO INCREASE DISTRIBUTION CAPACITY IN NORTH AMERICA, LATIN AMERICA, AND SOUTH KOREA
ZINZINO AB (PUBL.): INTERIM REPORT FIRST QUARTER 2025
ZINZINO AB (PUBL.): Zinzino acquires Valentus Global to increase distribution power in Europe
ZINZINO AB (PUBL.): PRELIMINARY SALES REPORT Q1 2025
ZINZINO AB (PUBL.): PRELIMINARY SALES REPORT FEBRUARY 2025
ZINZINO AB (PUBL.): YEAR-END REPORT 2024
ZINZINO AB (PUBL.): ANNOUNCES ACQUISITION OF ZURVITA'S ASSETS FOLLOWING SUCCESSFUL CHAPTER 11 PROCESS
ZINZINO AB (PUBL.): PRELIMINARY SALES REPORT JANUARY 2025
ZINZINO AB (PUBL.): ENTERS INTO AGREEMENT TO PROVIDE DIP FINANCING TO ZURVITA INITIATING CHAPTER 11 PROCESS